Matthew P. Blischak - Jun 8, 2023 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Chief Executive Officer
Signature
By: /s/ Matthew P. Blischak
Stock symbol
FNCH
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/9/2023, 04:52 PM
Previous filing
May 16, 2023
Next filing
Jun 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNCH Stock Option (right to buy) Award $0 +963K $0.00 963K Jun 8, 2023 Common Stock 963K $0.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option shall vest on June 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.